Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy

References

• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Barr RD, Saleh M, Furlong W, et al. Health status and health-related quality of life associated with hemophilia. Am J Hematol. 2002;71(3):152–160. doi:10.1002/ajh.10191
   PubMed Web of Science ®Google Scholar
• Forsyth AL, Witkop M, Lambing A, et al. Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study. Patient Prefer Adherence. 2015;9:1549–1560. doi:10.2147/PPA.S87659
   PubMed Web of Science ®Google Scholar
• Limperg PF, Haverman L, Maurice-Stam H, et al. Health-related quality of life, developmental milestones, and self-esteem in young adults with bleeding disorders. Qual Life Res. 2018;27(1):159–171. doi:10.1007/s11136-017-1696-0
   PubMed Web of Science ®Google Scholar
• Witkop M, Neff A, Buckner TW, et al. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the pain, Functional Impairment, and Quality of life (P-FiQ) study. Haemophilia. 2017;23(4):556–565. doi:10.1111/hae.13214
   PubMed Web of Science ®Google Scholar
• Mercan A, Sarper N, Inanir M, et al. Hemophilia-specific quality of life index (Haemo-QoL and Haem-A-QoL questionnaires) of children and adults: result of a single center from Turkey. Pediatr Hematol Oncol. 2010;27(6):449–461. doi:10.3109/08880018.2010.489933
   PubMed Web of Science ®Google Scholar
• Ozelo M, Chowdary P, Regnault A, Busk A. Impact of severe haemophilia A on patients’ health status: results from The Guardian™ 1 clinical trial of turoctocog alfa (NovoEight®). Haemophilia. 2015;21(4):451–457. doi:10.1111/hae.12617
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–818. doi:10.1056/NEJMoa1703068
   PubMed Web of Science ®Google Scholar
• Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence. 2017;11:1677–1686. doi:10.2147/PPA.S139851
   PubMed Web of Science ®Google Scholar
• Castaman G, Santoro C, Coppola A, et al. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfus. 2020;18(2):143–151. doi:10.2450/2019.0186-19
   PubMed Web of Science ®Google Scholar
• Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe Hemophilia A. N Engl J Med. 2017;377(26):2519–2530. doi:10.1056/NEJMoa1708483
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for Hemophilia A. N Engl J Med. 2020;382(1):29–40. doi:10.1056/NEJMoa1908490
   PubMed Web of Science ®Google Scholar
• George LA, Ragni MV, Samelson-Jones BJ, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130(Suppl 1):604.
   Google Scholar
• Pasi KJ, Laffan M, Rangarajan S, et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia. 2021;27(6):947–956. doi:10.1111/hae.14391
   PubMed Web of Science ®Google Scholar
• Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013–1025. doi:10.1056/NEJMoa2113708
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736. doi:10.1007/s11136-011-9903-x
   PubMed Web of Science ®Google Scholar
• O’Hara J, Martin AP, Nugent D, et al. Evidence of a disability paradox in patient-reported outcomes in haemophilia. Haemophilia. 2021;27(2):245–252. doi:10.1111/hae.14278
   PubMed Web of Science ®Google Scholar
• O’Hara J, Hughes D, Camp C, Burke T, Carroll L, Diego DG. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106. doi:10.1186/s13023-017-0660-y
   PubMed Web of Science ®Google Scholar
• Rentz A, Flood E, Altisent C, et al. Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia. Haemophilia. 2008;14(5):1023–1034. doi:10.1111/j.1365-2516.2008.01812.x
   PubMed Web of Science ®Google Scholar
• Wharfe G, Buchner-Daley L, Gibson T, et al. The Jamaican Haemophilia registry: describing the burden of disease. Haemophilia. 2018;24(4):e179–e186. doi:10.1111/hae.13517
   PubMed Web of Science ®Google Scholar
• Sun HL, McIntosh KA, Squire SJ, et al. Patient powered prophylaxis: a 12-month study of individualized prophylaxis in adults with severe haemophilia A. Haemophilia. 2017;23(6):877–883. doi:10.1111/hae.13319
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Lundin B, Funk S, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost. 2017;15(11):2115–2124. doi:10.1111/jth.13811
   PubMed Web of Science ®Google Scholar
• Limperg P, Terwee C, Young N, et al. Health‐related quality of life questionnaires in individuals with haemophilia: a systematic review of their measurement properties. Haemophilia. 2017;23(4):497–510. doi:10.1111/hae.13197
   PubMed Web of Science ®Google Scholar
• Bullinger M, Gardner DL, Lewis HB, et al. The potential impact of gene therapy on health-related quality of life (HRQoL) domains in haemophilia. J Haemophilia Pract. 2021;8(1):56–68. doi:10.17225/jhp00176
   Google Scholar
• Streiner D, Norman G. Health Measurement Scales: A Practical Guide to Their Development and Use. 2nd ed. Oxford University Press; 1995.
   Google Scholar
• Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Discussion Paper 172. The University of York Centre for Health Economics; 1999.
   Google Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–592. doi:10.1097/01.MLR.0000062554.74615.4C
   PubMed Web of Science ®Google Scholar
• Kaplan RM. The minimally clinically important difference in generic utility-based measures. COPD. 2005;2(1):91–97. doi:10.1081/copd-200052090
   PubMedGoogle Scholar
• US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:1–20. doi:10.1186/1477-7525-4-1
   PubMed Web of Science ®Google Scholar
• Valluri S, Flood E, Mink D, Bell J, Pocoski J, Sasane R. Determination of the minimal important difference (mid) of the hemophilia-specific quality of life questionnaire (Hemo-QOL-A) for adults with severe hemophilia A: PO-TU-233. Haemophilia. 2012;18(Suppl. 3):180–181.
   Google Scholar
• Gandhi M, Tan RS, Ng R, et al. Comparison of health state values derived from patients and individuals from the general population. Qual Life Res. 2017;26(12):3353–3363. doi:10.1007/s11136-017-1683-5
   PubMed Web of Science ®Google Scholar
• Peeters Y, Stiggelbout AM. Health state valuations of patients and the general public analytically compared: a meta-analytical comparison of patient and population health state utilities. Value Health. 2010;13(2):306–309. doi:10.1111/j.1524-4733.2009.00610.x
   PubMed Web of Science ®Google Scholar